Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer-Reference-Cited by-同舟云学术

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer

Published:2021-01-01 Issue:1 Volume:7 Page:78
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Zsiros Emese¹²,Lynam Sarah¹,Attwood Kristopher M.³,Wang Chong³,Chilakapati Shanmuga²,Gomez Eduardo Cortes³,Liu Song³,Akers Stacey¹,Lele Shashikant¹,Frederick Peter J.¹,Odunsi Kunle¹²

Affiliation:

1. Department of Gynecologic Oncology, Clinical Sciences Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York

2. Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York

3. Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2773114/jamaoncology_zsiros_2020_oi_200087_1609897954.35761.pdf

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.;Bray;CA Cancer J Clin,2018